Ticker LaunchIPO · THRD
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc. (THRD) priced its initial public offering on Sep 15, 2022 at $17.00 per share, within its $16.00–$18.00 range, raising $185.3M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $657.8M. Fenwick & West advised the company and Cooley advised the underwriters.
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for allergic and inflammatory diseases. Its lead candidate, THB001, is a highly selective oral small molecule inhibitor of KIT, a receptor regulating mast cells.
- Status
- IPO
- Ticker
- THRD
- Exchange
- Nasdaq Global Market
- Priced
- Sep 15, 2022
- IPO price
- $17.00
- Price range
- $16.00–$18.00
- Raised
- $185.3M
- Market cap at IPO price
- $657.8M
- First filed
- Aug 23, 2022
- Company counsel
- Fenwick & West
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Aug 23, 2022
- Latest amendment Sep 8, 2022
- Final prospectus (424B4) Sep 15, 2022
- All filings on EDGAR CIK 1923840
Other Biotech & pharma IPOs in 2022
- Prime Medicine, Inc.PRME · Oct 21, 2022 · $175M
- bioAffinity Technologies, Inc.BIAF · Sep 2, 2022 · $7.9M
- Shuttle Pharmaceuticals Holdings, Inc.SHPH · Aug 31, 2022 · $10M
- Kuvatris Therapeutics, Inc.PXMD · Aug 29, 2022
- MAIA Biotechnology, Inc.MAIA · Jul 29, 2022 · $10M
- Virax Biolabs Group LtdVRAX · Jul 21, 2022